A systematic review of outcomes associated with withholding or continuing angiotensinconverting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) prior to noncardiac surgery

dc.contributor.advisorBiccard, Bruce
dc.contributor.authorHollmann, Caryl
dc.date.accessioned2020-04-23T14:18:40Z
dc.date.available2020-04-23T14:18:40Z
dc.date.issued2019
dc.date.updated2020-04-23T01:18:40Z
dc.description.abstractIntroduction The global rate of major noncardiac surgical procedures is increasing annually, and of those patients presenting for surgery increasing numbers are taking either an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin receptor blocker(ARB). The current recommendations whether to continue or withhold ACE-I and ARB in the perioperative period are conflicting. Previous metaanalyses have linked preoperative ACE-I /ARB therapy to the increased incidence of post induction hypotension, however have failed to correlate this with adverse patient outcomes. The aim of this meta-analysis was to determine whether continuation or withholding ACE-I or ARB therapy in the perioperative period is associated with mortality and major morbidity. Methods This meta-analysis was prospectively registered on PROSPERO (CRD42017055291). A comprehensive search of MEDLINE (PubMed), CINAHL (EBSCO host), ProQuest, Cochrane database, Scopus and Web of Science was conducted on 06 December 2016. We included adult patients >18years, on chronic ACE-I or ARB therapy who underwent noncardiac surgery, where ACE-I or ARB was either withheld or continued on the morning of surgery. Primary outcomes included all-cause mortality and major cardiac events (MACE). Secondary outcomes included the risk of congestive heart failure (CHF), acute kidney injury, stroke, intra/postoperative hypotension and the length of hospital stay (LOS). Results Following abstract review, the full text of 25 studies were retrieved, of which nine fulfilled the inclusion criteria; five were randomized control trials (RCTs) and four cohort studies. These studies included a total of 6022 patients on chronic ACE-I/ARB therapy prior to noncardiac surgery. 1816 patients withheld treatment the morning of surgery and 4206 continued their ACE-I/ARB. Preoperative demographics were similar between the two groups. Withholding ACE-I/ARB therapy was not associated with a difference in mortality (odds ratio [OR], 0.97; 95% confidence interval [CI], 0.62-1.52; I2 =0%) or MACE (OR 1.12; 95% CI 0.82-1.52; I2 =0%). Withholding therapy was however associated with significantly less intra-operative hypotension (OR 0.63 95% CI 0.47;0.85, I 2 =71%). No effect estimate could be pooled concerning length of hospital stay and CHF. Conclusions This meta-analysis did not demonstrate an association between perioperative administration of ACEI/ARB, and mortality or MACE. It did however confirm the current observation that perioperative continuation of ACE-I/ARBs is associated with an increased incidence of intra-operative hypotension. A large randomized control trial is necessary to determine the appropriate perioperative management of ACE-I and ARBs.
dc.identifier.apacitationHollmann, C. (2019). <i>A systematic review of outcomes associated with withholding or continuing angiotensinconverting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) prior to noncardiac surgery</i>. (). ,Faculty of Health Sciences ,Department of Anaesthesia and Perioperative Medicine. Retrieved from en_ZA
dc.identifier.chicagocitationHollmann, Caryl. <i>"A systematic review of outcomes associated with withholding or continuing angiotensinconverting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) prior to noncardiac surgery."</i> ., ,Faculty of Health Sciences ,Department of Anaesthesia and Perioperative Medicine, 2019. en_ZA
dc.identifier.citationHollmann, C. 2019. A systematic review of outcomes associated with withholding or continuing angiotensinconverting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) prior to noncardiac surgery. . ,Faculty of Health Sciences ,Department of Anaesthesia and Perioperative Medicine. en_ZA
dc.identifier.ris TY - Thesis / Dissertation AU - Hollmann, Caryl AB - Introduction The global rate of major noncardiac surgical procedures is increasing annually, and of those patients presenting for surgery increasing numbers are taking either an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin receptor blocker(ARB). The current recommendations whether to continue or withhold ACE-I and ARB in the perioperative period are conflicting. Previous metaanalyses have linked preoperative ACE-I /ARB therapy to the increased incidence of post induction hypotension, however have failed to correlate this with adverse patient outcomes. The aim of this meta-analysis was to determine whether continuation or withholding ACE-I or ARB therapy in the perioperative period is associated with mortality and major morbidity. Methods This meta-analysis was prospectively registered on PROSPERO (CRD42017055291). A comprehensive search of MEDLINE (PubMed), CINAHL (EBSCO host), ProQuest, Cochrane database, Scopus and Web of Science was conducted on 06 December 2016. We included adult patients >18years, on chronic ACE-I or ARB therapy who underwent noncardiac surgery, where ACE-I or ARB was either withheld or continued on the morning of surgery. Primary outcomes included all-cause mortality and major cardiac events (MACE). Secondary outcomes included the risk of congestive heart failure (CHF), acute kidney injury, stroke, intra/postoperative hypotension and the length of hospital stay (LOS). Results Following abstract review, the full text of 25 studies were retrieved, of which nine fulfilled the inclusion criteria; five were randomized control trials (RCTs) and four cohort studies. These studies included a total of 6022 patients on chronic ACE-I/ARB therapy prior to noncardiac surgery. 1816 patients withheld treatment the morning of surgery and 4206 continued their ACE-I/ARB. Preoperative demographics were similar between the two groups. Withholding ACE-I/ARB therapy was not associated with a difference in mortality (odds ratio [OR], 0.97; 95% confidence interval [CI], 0.62-1.52; I2 =0%) or MACE (OR 1.12; 95% CI 0.82-1.52; I2 =0%). Withholding therapy was however associated with significantly less intra-operative hypotension (OR 0.63 95% CI 0.47;0.85, I 2 =71%). No effect estimate could be pooled concerning length of hospital stay and CHF. Conclusions This meta-analysis did not demonstrate an association between perioperative administration of ACEI/ARB, and mortality or MACE. It did however confirm the current observation that perioperative continuation of ACE-I/ARBs is associated with an increased incidence of intra-operative hypotension. A large randomized control trial is necessary to determine the appropriate perioperative management of ACE-I and ARBs. DA - 2019 DB - OpenUCT DP - University of Cape Town KW - Anaesthesiology LK - https://open.uct.ac.za PY - 2019 T1 - A systematic review of outcomes associated with withholding or continuing angiotensinconverting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) prior to noncardiac surgery TI - A systematic review of outcomes associated with withholding or continuing angiotensinconverting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) prior to noncardiac surgery UR - ER - en_ZA
dc.identifier.urihttps://hdl.handle.net/11427/31682
dc.identifier.vancouvercitationHollmann C. A systematic review of outcomes associated with withholding or continuing angiotensinconverting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) prior to noncardiac surgery. []. ,Faculty of Health Sciences ,Department of Anaesthesia and Perioperative Medicine, 2019 [cited yyyy month dd]. Available from: en_ZA
dc.language.rfc3066eng
dc.publisher.departmentDepartment of Anaesthesia and Perioperative Medicine
dc.publisher.facultyFaculty of Health Sciences
dc.subjectAnaesthesiology
dc.titleA systematic review of outcomes associated with withholding or continuing angiotensinconverting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) prior to noncardiac surgery
dc.typeMaster Thesis
dc.type.qualificationlevelMasters
dc.type.qualificationnameMMed
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
thesis_hsf_2019_Hollmann_Caryl.pdf
Size:
4.37 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Collections